When Marley Berthoud was born in 2015, her mother and father, Kelly and Brian Berthoud, knew instantly that something was wrong. Marley suffered from low muscle tone, developmental delays, complete hair loss and difficulty regulating her blood sugar and body temperature.
For four years, her parents searched for answers as Marley remained nonverbal and unable to hold up her head or feed herself. The turning point came when genetic testing by Caleb Bupp at Corewell Health Helen DeVos Children’s Hospital and molecular research from André Bachmann at the Michigan State University College of Human Medicine identified a mutation in Marley’s ODC1 gene. This case established the first recognized diagnosis of Bachmann-Bupp syndrome.
Drawing on decades of protein research with ODC1, Bachmann identified an existing medication, difluoromethylornithine, or DFMO, which has long been used to treat West African sleeping sickness, to “turn down” Marley’s overactive protein. In late 2019, 4-year-old Marley became the first person in the world treated with DFMO for the condition.
As nurses, Kelly and Brian carefully weighed their options before taking the leap. And once they did, the results were dramatic. Within months, Marley’s hair, eyelashes and eyebrows grew back, and she sat up independently, gained strength and made major cognitive strides. Today, 11-year-old Marley communicates using an iPad, follows commands and brightens every room she enters with her big smile.
This historic milestone proved that bridging the gap between laboratory research and bedside care could open new doors for families of children with rare diseases who felt like they had no medical options. This important alignment was recently recognized by the National Institutes of Health, or NIH, with a new $7.6 million NIH U54 grant awarded jointly to the MSU College of Human Medicine and Corewell Health.
“I’m a scientist and university professor, not a physician,” Bachmann said. “There is no way I could do this without Dr. Bupp and his team at Corewell Health because they are the ones who care for the patients. But at the same time, they could never have done this without our academic laboratory expertise. It is a mutually beneficial partnership, and neither of us would have achieved this alone.”
Translating years of lab experiments into real-world patient progress brought a profound sense of purpose to the entire research team.
“It is so fulfilling when you see your laboratory research translate directly into helping a child at the clinic,” Bachmann added. “When we first saw Marley, she had no muscle tone, couldn’t sit up and needed a feeding tube. Today, she is communicating, taking steps and enjoying her life. Seeing a safe medication bring back a child’s strength and hair — and giving her family hope — goes beyond anything we could have imagined. This new grant lets us expand that hope to families everywhere with children who have Bachmann-Bupp Syndrome or related polyamine disorders.”
Bupp agreed that starting with one child’s story created a ripple effect that could help countless other families navigating rare genetic diagnoses.
“All of this work has been so rewarding because it started with a single patient, which is my favorite way to do research,” he said. “From a human standpoint, I don’t think there’s a better way to spend research funds than on rare diseases because what you learn in rare diseases, you can then expand to help so many others. This new grant comes at a beautiful point for us to take what we have built together over almost 10 years and change the direction steeply toward expanding this to help more patients and families.”
For Kelly and Brian, seeing Marley thrive has given their family a level of peace they once thought was impossible.
“I wholeheartedly believe that Marley’s comprehension would not be at the level we’re seeing today without this medication,” Kelly shared. “As a parent, I know without a doubt that she’s happy she’s here and she enjoys her life. I could not ask for anything more.”
The new funding will further support the existing Center for Polyamine Disorders, or CPD, which was founded by Bachmann and Bupp in 2017. The grant also welcomes MSU, Corewell Health and Johns Hopkins University, along with six clinical sites, into a prestigious national network of 20 research centers under the Rare Diseases Clinical Research Network. The center focuses on five related genetic conditions — Snyder-Robinson syndrome, DHPS deficiency, Faundes-Banka syndrome and DOHH disorder — within the same biological family, and Bachmann-Bupp syndrome leads the way with regard to treatment progress.
To date, treatment with DFMO through the CPD has successfully reversed key symptoms in five patients worldwide, with 24 children globally now diagnosed with Bachmann-Bupp syndrome. For this pioneering work, Bachmann was named the 2025 Michigan State University Innovator of the Year.
The new $7.6 million grant will help kids like Marley by enabling researchers to:
At the heart of the breakthrough is a deep, personal partnership between laboratory scientists, doctors and parent advocacy groups — such as the Snyder-Robinson Foundation and the nonprofit organization Every Cure, all of whom work side by side to ensure research stays connected to the real-world needs of children and families.
Beyond the science, this journey remains rooted in the extraordinary bond with the Berthoud family, whose courage paved the way for families around the globe. Today, Marley is an energetic 11-year-old who loves high-fives, spending time with her younger brother Jack, and making sure everyone she meets sees her infectious smile.
“We all want our children to do great things in the world, and she’s doing it at a younger age than a lot of kids,” Kelly said. “She’s had a profound impact on the medical community and the research community just because she was born. I would love for the team at the NIH to know that they entrusted this money to the greatest humans on earth. The world is seeing that they’re changing how medicine works and how research and care can work together.”